SOLAR-1 is another ongoing phase III clinical study designed to evaluate the use of alpelisib plus fulvestrant in ER/PR + Her2– advanced cancer patients after treatment with AI (NCT02437318). The gene discussed is ERBB2; the disease is cancer.